| Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 (NCT02000830) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2013-10-17 |
| Stannsoporfin With Light Therapy for Newborn Babies With Jaundice (NCT01887327) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2013-10-16 |
| Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993) (NCT02033096) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2008-10-20 |
| A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia (NCT00850993) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2008-08-01 |
| Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W) (NCT02685189) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2006-07-01 |
| Safety and Pharmacology of Stanate (NCT00115544) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2005-09-01 |
| Efficacy and Safety of Stannsoporfin in Neonates (NCT02685137) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 2002-05-01 |
| Compassionate Use of Stanate (TM) [Stannsoporfin] (NCT00076960) | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | |